4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
Title:
4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
Author:
Ramalingam, S.S. Balli, D. Ciuleanu, T-E. Pluzanski, A. Lee, J-S. Schenker, M. Bernabe Caro, R. Lee, K.H. Bartolucci, R. Audigier-Valette, C. Hellmann, M.D. Paz-Ares, L.G. Reck, M. Borghaei, H. Brahmer, J.R. O’Byrne, K. Tran, P. Spires, T. Geese, W.J. Agrawal, S.